Alzamend Neuro, Inc. (ALZN) - Form 8-K Summary
Business Context and Reporting Period
Date of Report: February 28, 2025
Company: Alzamend Neuro, Inc., a Delaware corporation and emerging growth company.
Event: Entry into a Material Definitive Agreement (Securities Purchase & Exchange Agreement) with a sophisticated investor.
Key Financial Metrics and Transaction Terms
This filing details a financing arrangement rather than standard operating results. Key financial terms include:
- Total Financing Capacity: Up to $5,000,000.00 (subject to a 5% discount).
- Instrument: Sale of up to 500 shares of Series C Convertible Preferred Stock and warrants to purchase common stock.
- Initial Exchange: Conversion of 97.7511 shares of Series A Preferred Stock to Series C Preferred Stock.
- Warrant Terms: Initial issuance of warrants to purchase 1,000,000 shares of Common Stock at an exercise price of $0.92125 per share. Previous warrants for 640,000 shares were cancelled.
- Preferred Stock Dividends: Cumulative cash dividends at an annual rate of 15% ($1,500.00 per share), payable in cash or additional Series C shares at the Purchaser's discretion.
- Conversion Floor: Conversion price is subject to a floor of $0.10 per share.
Material Changes and Transaction Structure
The agreement structures the financing into eight separate Tranche Closings:
- Tranche 1 (Initial): Exchange of Series A for Series C shares and issuance of new warrants.
- Tranche 2: Purchase of 75 shares for $725,000 on the earlier of April 29, 2025, or 15 days after a resale registration statement is effective.
- Tranches 3-7: Purchase of 75 shares for $725,000 on each of the five monthly anniversaries of the Second Tranche Closing.
- Tranche 8: Purchase of 50 shares for $475,000 on the sixth monthly anniversary of the Second Tranche Closing.
- Conditions: Closings are contingent on the Common Stock average closing price meeting a defined "Floor Price." The agreement automatically terminates if the initial exchange does not close by March 14, 2025.
Guidance, Risks, and Contingencies
- Stockholder Approval: Issuance of shares exceeding 19.99% of outstanding common stock requires stockholder approval. The Company agreed to file a proxy statement to obtain this approval.
- Registration Rights: The agreement includes a Registration Rights Agreement for the resale of securities.
- Investor Protections: The Purchaser holds a Right of First Refusal and participation rights in future financings for a two-year period, provided they fund at least $712,500 by April 15, 2025, and maintain a minimum holding of 25 Series C shares.
- Liquidation Preference: Series C Preferred Stock ranks senior to other classes of preferred stock (including Series B) in liquidation events.
- Unusual Items: The transaction involves a significant discount (5%) and a high dividend rate (15%) typical of distressed or high-growth capital raises.
Investor Verification Checklist
- Verify the status of the resale registration statement and the expected effectiveness date.
- Confirm whether the initial Exchange Closing occurred by the March 14, 2025 deadline.
- Review the proxy statement for the upcoming stockholder vote regarding the 19.99% issuance cap.
- Assess the Company's current cash position and burn rate relative to the $5 million financing target.
- Examine the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific termination triggers and anti-dilution mechanics.